ANCA targeting proteinase 3 (PR3) and myeloperoxidase (MPO) are implicated in the pathogenesis of AAV, and are a promising biomarker of rituximab efficacy. This evidence concerns the gene PRTN3 and anti-neutrophil cytoplasmic antibody-associated vasculitis.